Literature DB >> 27822851

SPECT-CT Comparison of Lung Deposition using a System combining a Vibrating-mesh Nebulizer with a Valved Holding Chamber and a Conventional Jet Nebulizer: a Randomized Cross-over Study.

Jonathan Dugernier1,2,3, Michel Hesse4, Rita Vanbever5, Virginie Depoortere4, Jean Roeseler6, Jean-Bernard Michotte7, Pierre-François Laterre6, François Jamar4, Gregory Reychler8,9,10.   

Abstract

PURPOSE: To compare in vivo the total and regional pulmonary deposition of aerosol particles generated by a new system combining a vibrating-mesh nebulizer with a specific valved holding chamber and constant-output jet nebulizer connected to a corrugated tube.
METHODS: Cross-over study comparing aerosol delivery to the lungs using two nebulizers in 6 healthy male subjects: a vibrating-mesh nebulizer combined with a valved holding chamber (Aerogen Ultra®, Aerogen Ltd., Galway, Ireland) and a jet nebulizer connected to a corrugated tube (Opti-Mist Plus Nebulizer®, ConvaTec, Bridgewater, NJ). Nebulizers were filled with diethylenetriaminepentaacetic acid labelled with technetium-99 m (99mTc-DTPA, 2 mCi/4 mL). Pulmonary deposition of 99mTc-DTPA was measured by single-photon emission computed tomography combined with a low dose CT-scan (SPECT-CT).
RESULTS: Pulmonary aerosol deposition from SPECT-CT analysis was six times increased with the vibrating-mesh nebulizer as compared to the jet nebulizer (34.1 ± 6.0% versus 5.2 ± 1.1%, p < 0.001). However, aerosol penetration expressed as the three-dimensional normalized ratio of the outer and the inner regions of the lungs was similar between both nebulizers.
CONCLUSIONS: This study demonstrated the high superiority of the new system combining a vibrating-mesh nebulizer with a valved holding chamber to deliver nebulized particles into the lungs as comparted to a constant-output jet nebulizer with a corrugated tube.

Entities:  

Keywords:  Aerosol delivery; Healthy subjects; Single photon emission computed tomography; Spacer; Vibrating-mesh nebulizer

Mesh:

Substances:

Year:  2016        PMID: 27822851     DOI: 10.1007/s11095-016-2061-7

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  48 in total

1.  Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects.

Authors:  Warren Lenney; Frank Edenborough; Pearl Kho; John M Kovarik
Journal:  J Cyst Fibros       Date:  2011-01       Impact factor: 5.482

2.  Variability in the measurement of nebulized aerosol deposition in man.

Authors:  S H Thomas; M J O'Doherty; C J Page; T O Nunan
Journal:  Clin Sci (Lond)       Date:  1991-12       Impact factor: 6.124

3.  Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation.

Authors:  E M Bakker; S Volpi; E Salonini; E C van der Wiel-Kooij; C J J C M Sintnicolaas; W C J Hop; B M Assael; P J F M Merkus; H A W M Tiddens
Journal:  Eur Respir J       Date:  2011-07-07       Impact factor: 16.671

4.  Standardization of techniques for using single-photon emission computed tomography (SPECT) for aerosol deposition assessment of orally inhaled products.

Authors:  John Fleming; Dale L Bailey; Hak-Kim Chan; Joy Conway; Philip J Kuehl; Beth L Laube; Stephen Newman
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2012-12       Impact factor: 2.849

5.  Effect of drug targeting nebulization on lung deposition: a randomized crossover scintigraphic comparison between central and peripheral delivery.

Authors:  Gregory Reychler; Anne-Sophie Aubriot; Virginie Depoortere; François Jamar; Giuseppe Liistro
Journal:  Respir Care       Date:  2014-08-26       Impact factor: 2.258

Review 6.  Emerging inhalation aerosol devices and strategies: where are we headed?

Authors:  Qi Tony Zhou; Patricia Tang; Sharon Shui Yee Leung; John Gar Yan Chan; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2014-04-13       Impact factor: 15.470

7.  Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis.

Authors:  Allan L Coates; Oliver Denk; Kitty Leung; Nancy Ribeiro; Jeffrey Chan; Maria Green; Sean Martin; Martin Charron; Michael Edwardes; Manfred Keller
Journal:  Pediatr Pulmonol       Date:  2010-12-30

8.  Systemic availability and lung deposition of budesonide via three different nebulizers in adults.

Authors:  Kerstin Dahlström; Lars Thorsson; Per Larsson; Kurt Nikander
Journal:  Ann Allergy Asthma Immunol       Date:  2003-02       Impact factor: 6.347

9.  Quantitative deposition of aerosolized gentamicin in cystic fibrosis.

Authors:  J S Ilowite; J D Gorvoy; G C Smaldone
Journal:  Am Rev Respir Dis       Date:  1987-12

Review 10.  Inhaled bronchodilator administration during mechanical ventilation.

Authors:  Alexander G Duarte
Journal:  Respir Care       Date:  2004-06       Impact factor: 2.258

View more
  14 in total

Review 1.  Review of aerosol delivery in the emergency department.

Authors:  Patricia A Dailey; Courtney M Shockley
Journal:  Ann Transl Med       Date:  2021-04

Review 2.  Devices for Improved Delivery of Nebulized Pharmaceutical Aerosols to the Lungs.

Authors:  Worth Longest; Benjamin Spence; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-07-09       Impact factor: 2.849

3.  Precise Targeting of miRNA Sites Restores CFTR Activity in CF Bronchial Epithelial Cells.

Authors:  Chiara De Santi; Elena Fernández Fernández; Rachel Gaul; Sebastian Vencken; Arlene Glasgow; Irene K Oglesby; Killian Hurley; Finn Hawkins; Nilay Mitash; Fangping Mu; Rana Raoof; David C Henshall; Meritxell B Cutrona; Jeremy C Simpson; Brian J Harvey; Barry Linnane; Paul McNally; Sally Ann Cryan; Ronan MacLoughlin; Agnieszka Swiatecka-Urban; Catherine M Greene
Journal:  Mol Ther       Date:  2020-02-06       Impact factor: 11.454

4.  In Vitro and In Vivo Assessment of PEGylated PEI for Anti-IL-8/CxCL-1 siRNA Delivery to the Lungs.

Authors:  Alan J Hibbitts; Joanne M Ramsey; James Barlow; Ronan MacLoughlin; Sally-Ann Cryan
Journal:  Nanomaterials (Basel)       Date:  2020-06-27       Impact factor: 5.076

5.  Evaluation of Aerosol Therapy during the Escalation of Care in a Model of Adult Cystic Fibrosis.

Authors:  Elena Fernández Fernández; Mary Joyce; Andrew O'Sullivan; Ronan MacLoughlin
Journal:  Antibiotics (Basel)       Date:  2021-04-21

6.  Biopolymer-Based Nanoparticles for Cystic Fibrosis Lung Gene Therapy Studies.

Authors:  Elena Fernández Fernández; Beatriz Santos-Carballal; Chiara de Santi; Joanne M Ramsey; Ronan MacLoughlin; Sally-Ann Cryan; Catherine M Greene
Journal:  Materials (Basel)       Date:  2018-01-13       Impact factor: 3.623

Review 7.  Aerosol delivery during invasive mechanical ventilation: a systematic review.

Authors:  Jonathan Dugernier; Stephan Ehrmann; Thierry Sottiaux; Jean Roeseler; Xavier Wittebole; Thierry Dugernier; François Jamar; Pierre-François Laterre; Gregory Reychler
Journal:  Crit Care       Date:  2017-10-21       Impact factor: 9.097

8.  Distribution of Droplets and Immune Responses After Aerosol and Intra-Nasal Delivery of Influenza Virus to the Respiratory Tract of Pigs.

Authors:  Veronica Martini; Michael Hinchcliffe; Elaine Blackshaw; Mary Joyce; Adam McNee; Peter Beverley; Alain Townsend; Ronan MacLoughlin; Elma Tchilian
Journal:  Front Immunol       Date:  2020-10-27       Impact factor: 7.561

9.  The Impact of Head Model Choice on the In Vitro Evaluation of Aerosol Drug Delivery.

Authors:  Lauren Gallagher; Mary Joyce; Barry Murphy; Marc Mac Giolla Eain; Ronan MacLoughlin
Journal:  Pharmaceutics       Date:  2021-12-23       Impact factor: 6.321

10.  Effect of MDI Actuation Timing on Inhalation Dosimetry in a Human Respiratory Tract Model.

Authors:  Mohamed Talaat; Xiuhua Si; Jinxiang Xi
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.